Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

58P - Real-world data of incidence of immune related toxicities with single agent immuno oncology drugs at a single center


09 Dec 2020


e-Poster Display Session



Tumour Site


Goteti Sharat Chandra


Annals of Oncology (2020) 31 (suppl_7): S1428-S1440. 10.1016/annonc/annonc391


G. Sharat Chandra1, M. Singhal2, A. Sharma2, S. Valame2, D. Panda2

Author affiliations

  • 1 Medical Oncology, Indraprastha Apollo Hospital, 110076 - New Delhi/IN
  • 2 Indraprastha Apollo Hospital, New Delhi/IN

Abstract 58P


IO agents have revolutionised the treatment in many solid cancers leading to improved overall survival and also quality of life. Although well tolerated, immune related toxicities have been an issue. Data about the same from the real world practise is little known.


We aimed to evaluate the toxicity profile of IO agents across different solid cancers at our center .Consecutive patients who were treated with IO regimens between Jan 2018 and Feb 2020 were prospectively analysed for Immune related toxicities .They were graded as per Common Terminology Criteria for Adverse Events and managed as per NCCN guidelines for Immune Related Toxicities .All patients who received at least 2 doses of IO agents were included in the study.


Between Jan 2018 and Feb 2020 ,115 patients were eligible and analysed for immune related toxicities .There were 62 females (53.9%) and 53 males (46.1%) .IO agents used were Nivolumab (n=56) ,Pembrolizumab (n=40) ,Atezolizumab (n=14) and Durvalumab (n=5) .Among different indications ,Metastatic NSCLC (21.7%) ,Bladder (12.1%) ,RCC (12.1%),HCC (11.3%) were most common .Incidence of all grades Immune Related Toxicities was 68.6% (n=79) .Grade ½ was seen in 60% (n=69) and grade ¾ was seen in 8.6%(n=10) .Most common toxicities were Hypothyroidism (35.4%) ,Pneumonitis(20.2%) ,Colitis (12.6%) ,Adrenal (7.5%) ,Hepatic (6.3%) ,Dermatologic (3.7%) ,Renal (3.7%) and Diabetes (3.7%) .Grade ¾ toxicities encountered were Pneumonitis (n=3) ,Colitis (n=2) ,GBS (n=1) ,Nephritis (n=1), Pancreatitis (n=1) ,Hypophysitis (n=1) and Hepatitis (n=1) .Grade 4 toxicity lead to 4 deaths in our study period.


Immune Related Toxicities are as common in the real world as in the trial population often leading to discontinuation of the drug .Our study depicts the incidence of different toxicities encountered with single agent IO drugs at a single center.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.